|
|
|
Volumn 31, Issue 12, 2007, Pages 118-132
|
|
Converting intravenous dosing to subcutaneous dosing: With recombinant human hyaluronidase
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
INTRAVENOUS DOSING;
RECOMBINANT HUMAN HYALURONIDASE;
DNA SEQUENCES;
DRUG DELIVERY;
ENZYME ACTIVITY;
GENES;
PROTEINS;
DRUG DOSAGE;
ADALIMUMAB;
ALEMTUZUMAB;
ALKYLATING AGENT;
ETANERCEPT;
FLUDARABINE;
GLYCOSAMINOGLYCAN;
HEPARIN;
HYALURONIDASE;
INFLIXIMAB;
INSULIN;
METHOTREXATE;
PEGINTERFERON ALPHA2B;
RHUPH20 ENZYME;
UNCLASSIFIED DRUG;
ARTICLE;
COMBINATION CHEMOTHERAPY;
COST EFFECTIVENESS ANALYSIS;
CROHN DISEASE;
DRUG BIOAVAILABILITY;
DRUG DELIVERY SYSTEM;
DRUG DOSAGE FORM;
DRUG MANUFACTURE;
EXTRACELLULAR MATRIX;
HUMAN;
LYMPHATIC LEUKEMIA;
NONHUMAN;
PHARMACEUTICAL ENGINEERING;
RHEUMATOID ARTHRITIS;
|
|
EID: 40149098056
PISSN: 15432521
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (11)
|
|
References (44)
|
